What is it about?
The non-clinical pharmacokinetic profiles of rovatirelin, a novel thyrotropin-releasing hormone (TRH) analogue, were investigated in vivo and in vitro. Rovatirelin was rapidly absorbed after oral administration to rats and dogs, and the bioavailability was moderate. The transition of rovatirelin from blood into the cerebrum and cerebellum were observed to be adequate in rats, and rovatirelin was stable in rat plasma and brain homogenates. The absorption, transition to brain, and stability in brain of rovatirelin are thought to be greater than for taltirelin. Thus, we suggest that, in addition to taltirelin, rovatirelin is a potential oral drug for the treatment of spinocerebellar degeneration .
Featured Image
Why is it important?
Rovatirelin is a novel TRH analogue
Read the Original
This page is a summary of: Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue, Xenobiotica, January 2018, Taylor & Francis,
DOI: 10.1080/00498254.2017.1423130.
You can read the full text:
Contributors
The following have contributed to this page
